Biocept

Biocept Treasury Stock

Delisted

The Treasury Stock of Biocept (BIOC) as of Nov 3, 2026 is 307.30 M USD. In the previous year, Treasury Stock was 303.83 M USD — a change of 1.14% (higher).

Treasury Stock

307.30 MUSD

YoY

1.14%

Last updated:

Treasury Stock of Biocept is 2022 307.30 M USD. Treasury Stock of Biocept was 2021 303.83 M USD. It decreases by 1.14% higher compared to the previous year.

The Biocept Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2015
158.93 M USD
Jan 1, 2016
174.29 M USD
Jan 1, 2017
196.54 M USD
Jan 1, 2018
228.43 M USD
Jan 1, 2019
256.91 M USD
Jan 1, 2020
287.22 M USD
Jan 1, 2021
303.83 M USD
Jan 1, 2022
307.30 M USD
The Biocept Treasury Stock history
YEARTreasury StockYoY
307.30 MUSD+1.14%
303.83 MUSD+5.78%
287.22 MUSD+11.80%
256.91 MUSD+12.47%
228.43 MUSD+16.23%
196.54 MUSD+12.77%
174.29 MUSD+9.67%
158.93 MUSD+15.11%
138.07 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Treasury Stock of Biocept is 307.30 M USD in 2022.

Treasury Stock of Biocept changed from 303.83 M USD to 307.30 M USD, representing a 1.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock Biocept since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's Biocept historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biocept

All Key Metrics — Biocept